شماره تماس 09371686566   
لطفا جهت خرید کتب چاپی استعلام قیمت جدید بگیرید
وارد شوید
x
یا
x
ثبت
x

یا

دانلود کتاب Overcoming Drug Resistance in Gynecologic Cancers (Volume 17) (Cancer Sensitizing Agents for Chemotherapy, Volume 17) 2021 (ORIGINAL PDF)

240,000 تومان
کد : 3016
انتخاب ها:


نام کتاب: Overcoming Drug Resistance in Gynecologic Cancers (Volume 17) (Cancer Sensitizing Agents for Chemotherapy, Volume 17) 1st Edition

 

نويسنده/نويسندگان: Riyaz Basha (Editor), Sarfraz Ahmad (Editor)
نوع فايل: ORIGINAL PDF
تعداد صفحات : 388
ناشر : Academic Press
شابک : 9780128242995
نسخه چاپی تمام رنگی ، با کیفیت بالا ،جلد هارد

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers.

Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers.

Editorial Reviews

Review

Provides up-to-date information on the basic mechanisms of drug resistance, health disparities, commercial impacts and new strategies

From the Back Cover

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers focusing on the mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, and economic considerations/financial impact. It covers not only drug resistance but important means to reverse resistance both in the laboratory and clinic.

The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers; the financial impact of drug resistance; chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer; immunotherapy to overcome drug resistance; and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers.

It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers.

About the Author

Doctor Riyaz Basha is an Associate Professor & Vice Chair for Research in the Department of Pediatrics and Women’s Health, Texas College of Osteopathic Medicine, The University of North Texas Health Science Center (UNTHSC) at Fort Worth, TX, USA. He graduated with a PhD degree in 1999 from the Sri Venkateswara University, Tirupati, India, and received postdoctoral training at the University of Rhode Island, RI, USA. Before joining the UNTHSC in 2013, Dr. Basha was appointed as an Assistant Professor at the Cancer Research Institute of the MD Anderson Cancer Center at Orlando (currently named as UF Cancer Center), Orlando, FL, USA.

Dr. Basha’s research is focused on improving cancer therapies in children, adolescents and adults. He has been working closely with physicians and researchers with emphasis on the translational principle of “bench to bedside”. He has been investigating on drug resistance and novel strategies to improve the response of standard care/treatment, especially chemotherapy for various cancers including ovarian cancer. He has published his research findings in high impact factor journals such as Journal of Biological Chemistry, Cancer Letters, Cancer Medicine, Critical Reviews in Oncology/Hematology, and Gynecologic Oncology. Dr. Basha is a member of several scientific societies, including the Association of Biotechnology and Pharmacy (ABAP), American Association for Cancer Research, American Society of Clinical Oncology, and American Association for Clinical Chemistry (AACC) Academy. He became Fellow of the ABAP and the AACC Academies, respectively, in 2014 and 2019. He is the recipient of numerous competitive grants from the National Institutes of Health, Hyundai Hope On Wheels, non-profit foundations, and awards including the Young Scientist Travel Award from the Asian Pacific Society for Neurochemistry, four research presentation awards from the Society of Toxicology (USA), and the best presentation award at the International Conference on Drug Discovery and Therapy held in Dubai, UAE. Dr. Basha co-authored more than 100 peer-reviewed publications, served as Guest Editor for two journals, and serving as peer reviewer for more than 50 scientific journals. His research works are extensively cited by the peers globally.

Doctor Sarfraz Ahmad is Director of Clinical Research at the Gynecologic Oncology Department of the Advent Health (formerly Florida Hospital) Cancer Institute (AHCI), Orlando, FL, USA. He earned his PhD degree in Biochemistry from North-Eastern Hill University, Shillong. Before joining AHCI in 2002, he spent 2-years at the Indian Institute of Technology-Delhi as a researcher, and 10-years in research/teaching at the Loyola University of Chicago and the University of Illinois at Chicago’s Division of Hematology/Oncology, College of Medicine. Currently, he is Professor of Medical Education at the University of Central Florida, College of Medicine and Professor of Clinical Sciences at the Florida State University College of Medicine, Orlando, USA. He has trained numerous fellows, residents, medical students, and graduate/undergraduate students during their scholarly research projects and theses.

Dotor Ahmad’s current research focus is on the analyses of clinico-pathologic and surgical outcomes of oncology/hematology patients and to better understand the cellular/molecular mechanisms of cancer and related thrombo-embolic/hematologic disorders. His investigations are also aimed towards the evaluation of novel treatment options (chemo/cellular/immuno-therapies) for better management of hemato-oncologic patients. His past research interests focused on the anticoagulants, antithrombin, antiplatelet, and thrombolytic drug development for the management of hematologic and cardiovascular patients. In these various areas of biomedical research and international collaborations, Dr. Ahmad has published over 200 peer-reviewed scholarly research articles and book chapters, and nearly 400 scientific abstracts, which are extensively cited globally. He is a reviewer and has editorial responsibilities for several biomedical journals/books; he has received several competitive research grants and national/international awards for his research contributions/accomplishments. In addition to biomedical science endeavors, Dr. Ahmad is passionate about classical Hindi-Urdu literature & poetry and takes pride with active participation in such forums.

X

Right Click

No right click